The global market for cancer innovatives has more than tripled in size over the last four years, achieving a compound annual growth rate (CAGR) of 33.1% between 2003 and 2006. The current demand of nanotechnology based patient monitoring systems is expected to grow at a rate of 17.5% annually from its current levels of $ 7.5 Billion through 2011, driven by the critical need for new or improved therapies and diagnostics.

Using independently verified probe-biomarker combinations, we are developing multifunctional nanobindi probes for ultra sensitive and non invasive detection of various cancers using MR Imaging.